October 5, 2017, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the phase 1 results of its GLP-1R antibody Glutazumab at the coming International Diabetes Federation (IDF) Congress 2017. The IDF Congress 2017 will take place in Abu Dhabi, 4-8 December 2017.

Poster ID: P-0352
Abstract – AD-1719: A phase I study to investigate the safety, tolerability and pharmacokinetics of a biased GLP-1R antibody Glutazumab.